Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
why would IND get approved when it was rejected
one thing the FDA is looking for is data and there just isn't enough data and no peer review
have they finally halted trading on this POS
nothing to br proud of all 2nd rate doctors....didnt even know how to file an IND right
so it took pmcb 4 month to start one study on the list......kenny can pump these for years
No evidence as usual that ciab works
which is killing us in a month
this is all being fueled by the marijuana sector because PMCB is list as a marijuana stock.....until investor figure out its not......the dump is coming
REJECTED AND PUT ON HOLD
PMCBs IND still rejected by the FDA
Ciab= cash in the box for kenny
frankly I dont know what you are saying
IND was rejected 3 days after PMCB summit it to the FDA......its spell out in the 10Q for all to read
But they do care when the FDA rejected pmcbs ind
Tesla has a product PMCB has nothing
Kennys not smart
sooner of later kenny will have to reveal the fraud......but he will fall back on we tried but it just didn't work
$30 with a product not 2 cents with no hope of ever having a product
where the IND haven't seen it..... oh that right thats the pump
PMCB to announce the Hong Kong vaccine....coming soon...it will be the best of the best......the military will be using it......will be available April 15th or sooner by march 18th
PMCB can't treat anything it was rejected by the FDA
FDA rejected PMCBs IND and there is nothing they can do about
where is the gap up today for PMCB? maybe on 3/18 lol
figures
yes my group has bought discounted shares and sell into the run up created by PMCB.....no 13 d owership filing required we keep it under 5%
PMCB has not check one thing off the list since IND was rejected by the FDA 3 days after it was filed
what a lame name
never going to happen....the man is a coward
what does the L stand for.... kenny Loser wagey
KENNIS LICINIUS WAGRICANUS FRAUDOSIS
Fda rejected pmcbs ind
Austrianova literately a horse and pony show, they are veterinarians
Quote Im thinking partnership in the first or second week of Feb.
where the partnership
LOL
PharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now Considering
(GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) may have what the White House Coronavirus Task Force is looking for just as COVID-19 cases are surging across the country. Last week, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the White House Coronavirus Task Force is now considering sample pooling, also known as pool testing, as a way to ramp up local authorities’ ability to determine the extent of the infection in their areas.
“It’s not going well. I have to tell you, it’s not going well,” Dr. Fauci said in an interview with CNBC. “What we need to do is we need to rethink, and we are right now, the idea of many more tests getting into the community and even pooling tests.”
Pool testing involves combining or pooling samples from multiple people and testing them together in a single batch. It’s a way to efficiently increase the volume of tests to quickly churn through what is expected to be mostly negative samples.
PharmaCyte’s COVID-19 testing kits have exactly that capability. The company licensed its COVID-19 test from Hai Kang Life Corporation in Hong Kong and is currently awaiting Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). One of the key selling points for PharmaCyte’s testing kits is that they are ideally suited for the mass testing that Dr. Fauci is convinced will make a difference.
Dr. Deborah Birx, who along with Dr. Fauci play a lead role on the White House Coronavirus Task Force, said, “Pooling would give us the capacity to go from half a million tests a day to potentially 5 million individuals tested per day.”
In addition to combating the recent surge in coronavirus cases, PharmaCyte’s COVID-19 test could be the perfect option to ensure a safer reopening of the entire country with a mass-testing solution in place that all companies, organizations, schools, and universities could embrace with confidence.
It was in April of this year that a report titled, “Roadmap to Pandemic Resilience,” was released by a blue-ribbon panel of thought leaders across the political spectrum which included economists, social scientists, lawyers and ethicists, and according to that report, there's a growing consensus that points to one key move necessary to put Americans back to work—dramatically upscaling testing.
During a recent Coronavirus Task Force briefing, it was reported that 48 separate coronavirus tests have been authorized and that the U.S. FDA is working with 300 companies and laboratories to widen the nation's testing capacity. According to the “Roadmap to Pandemic Resilience” report, “test producers will need to deliver 5 million tests per day to safely open parts of the economy by late July,” and to “fully re-mobilize the economy, the country will need to see testing grow to 20 million a day.”
With numbers like these, it’s clear that many more testing companies will need to join the fight to improve the daily testing requirement. PharmaCyte’s COVID-19 test should move to the front of the line once its Emergency Use Authorization is granted by the FDA because not only does its developer, Hai Kang’s founder and current Chairman, Professor Albert Cheung-Hoi Yu, Ph.D., call it the “most sensitive test in the world” to detect the virus that causes COVID-19, but also because of its capability to offer pool testing.
PharmaCyte’s COVID-19 test is capable of testing hundreds of people at one time using “sample pooling” or “population screening.” The ability to test hundreds at one time will allow PharmaCyte to leverage the sensitivity of the test to local, state and government agencies, communities, companies, organizations, schools, etc., to test a pool of employees to get these entities back to work while giving them the means to do continuous testing into the future, which will create a safer environment for employees to feel comfortable in the workplace.
Professor Yu said of the ability of this COVID-19 test to do pool testing, “Where large volumes of tests are required, pooling of samples for ERT-PCR testing can increase sample throughput. The pooling strategy expedites the screening process for which the accuracy can be ensured by the highly sensitive ERT-PCR test method.”
Sample pooling is accomplished by swabbing a large group and then each of the samples is pooled into 1 “test reaction,” and if the test results are negative, then everyone in the group is free of the virus. However, if the test results are positive, then each person in that pool will be tested individually to determine who among them has the virus.
This capability is possible because the company’s COVID-19 test is extremely sensitive thus eliminating the potential for false-negative results. According to Professor Yu, the reason the test is so sensitive is that it can detect the virus well below the threshold, “Compared to the routine RT-PCR tests, our test is more sensitive. Its limit of detection is down to 1-2 copies (of RNA) per reaction, so it is most useful for the detection of infections where the viral load is low, for example, during the pre-symptomatic and post-symptomatic phases and for asymptomatic cases. These situations are where the routine RT-PCR tests most likely give false-negative results.”
He continued, “In comparison with antibody-based tests, because they have a delay time before the antibodies reach detectable levels, likely post-infection over seven days, our test is more accurate than antibody-based tests for early detection.”
It is very likely that the United States will need to undergo testing for COVID-19 well beyond 2020 and potentially forever.
Professor Yu agrees, “There is speculation that there may be a second wave and there is the suggestion that the disease will become a seasonal disease. It is therefore imperative that random screening for SARS-CoV-2 (COVID-19) continues even after the first wave of the disease subsides so that we can monitor for its re-emergence. Our ERT-PCR is best suited for this purpose because it allows for sample pooling and detection of low viral loads.”
The test for SARS-CoV-2 that PharmaCyte licensed from Hai Kang Life was developed when Professor Yu and his team re-examined the same technology and methods that were used when they developed the successful test for the original SARS-CoV (SARS) virus and found that the test is also applicable to the new coronavirus. It’s a test that was published in The New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJM200404083501523) after it proved to be more sensitive, reliable, and accurate in detecting the SARS virus during the 2002-2003 outbreak in China.
I would say Thermo Fisher Scientific would have the advantage to buyout PMCB as David Judd is now associated with PMCB...
lol
Hmmm..ok...even though pmcb has filed an IND with the FDA for a phase 2b and was rejected
looks like Pfizer took a large position in PMCB now that something very good mmmm
I guess Tom Liquard started feeling it was time to talk to Phizer about PMCB and what they have going on right now. the time couldnt be any better.
Thomas Liquard was appointed to the Board in April 2015. Mr. Liquard has more than a decade of experience in the pharmaceutical industry, having held various commercialization, product development and leadership roles with big pharma and biotech companies. From 2013 to 2014, Mr. Liquard was COO then CEO of Alchemia Limited (Alchemia), a major Australian biotech company (ASX: ACL) with an FDA-approved sterile injectable and a late stage oncology platform. During that time, Mr. Liquard administered an AU$ 25 million budget and Alchemia had revenues of AU$ 15 million. While at Alchemia, Mr. Liquard rebuilt that company’s valuation which had lost 23% after the departure of the prior CEO, brought two major investors into the register, improved its stock price to a 52-week high and led all business development and corporate development activities.
Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer, Inc. (Pfizer) in New York, where he held various commercial roles of increasing scope and responsibility, including most recently as Senior Director, Portfolio Development Leader and Emerging Markets for the Established Products portfolio. In that role, Mr. Liquard drove business development (M&A, licensing, partnerships) and internal product development initiatives and managed more than 70 opportunities at various stages of execution. During his tenure at Pfizer, Mr. Liquard also spent three years as a key member of the company’s Established Products US Brands P&L Leadership Team where he engineered the group’s 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals, Inc. (NextWave). He also led the NextWave pre- and post- acquisition integration efforts. In addition, Mr. Liquard worked as a Director within the New Product Planning and Portfolio & Decision Analysis groups at Pfizer from 2007 to 2010. There he was responsible for formulating investment decisions on business development opportunities and internal development programs across multiple therapeutic areas including oncology and metabolic diseases, including diabetes and central nervous system.
watch the bullish action next week .03 .04 maybe .05..... lol
Quote Im thinking partnership in the first or second week of Feb.
so far IND has been reject by the FDA